Key result
Compared with warfarin, dabigatran b.i.d. lowered stroke and systemic embolism risk with similar major hemorrhage, whereas b.i.d. had similar stroke risk but lower major hemorrhage.
Why the study?
Does dabigatran reduce stroke and systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
Does dabigatran reduce stroke and systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
This review highlights that dabigatran is an effective and safe alternative to warfarin for stroke prevention across various subgroups of patients with nonvalvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports dabigatran dosing in nonvalvular AF; leaves open optimal selection pending prospective confirmation.
INTRODUCTION: Nonvalvular atrial fibrillation (NVAF) is associated with a fivefold excess risk of stroke. Antithrombotic therapy is crucial to reduce the risk of stroke. During past decades, vitamin K antagonists (warfarin or acenocoumarol) have been widely used for this purpose. However, they have several disadvantages that limit their daily use in clinical practice. AREAS COVERED: In patients with NVAF at risk of stroke, the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial demonstrated that, compared with warfarin, dabigatran 150 mg b.i.d. was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage, whereas dabigatran 110 mg b.i.d. exhibited similar rates of stroke and systemic embolism, but lower rates of major hemorrhage. Fortunately, data about dabigatran are not limited to RE-LY trial. In fact, many substudies have been drawn, providing new and important evidences about the benefits of dabigatran. EXPERT OPINION: The most recent evidences about efficacy and safety of dabigatran in patients with NVAF, focusing on different substudies of RE-LY trial, are reviewed. In summary, dabigatran is beneficial not only in general population with NVAF but also in different subgroups of patients or different clinical settings (i.e., CHADS2 score, INR control, type of AF, elderly, previous transient ischemic attack or stroke, cardioversion and so on).
No takes yet. Share an insight, caveat, or question.
Barrios et al. (2012) conducted a review in Nonvalvular atrial fibrillation (NVAF). Dabigatran vs. Warfarin was evaluated on Stroke and systemic embolism; major hemorrhage. Compared with warfarin, dabigatran b.i.d. lowered stroke and systemic embolism risk with similar major hemorrhage, whereas b.i.d. had similar stroke risk but lower major hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: